| 发明名称 | Tyrosine kinase inhibitors | ||
| 摘要 | The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof. | ||
| 申请公布号 | US8962831(B2) | 申请公布日期 | 2015.02.24 |
| 申请号 | US201214117933 | 申请日期 | 2012.05.16 |
| 申请人 | Principia Biopharma Inc. | 发明人 | Goldstein David Michael |
| 分类号 | C07D487/00;C07D487/04;A61K31/519;A61K31/5377;A61K45/06 | 主分类号 | C07D487/00 |
| 代理机构 | Finnegan, Henderson, Farabow, Garrett & Dunner, LLP | 代理人 | Finnegan, Henderson, Farabow, Garrett & Dunner, LLP |
| 主权项 | 1. 3-(2-Fluoro-4-phenoxyphenyl)-1-[(3R)-piperidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine having the structure or a salt thereof. | ||
| 地址 | South San Franciso CA US | ||